Microfluidic device for forming three-dimensional tissue barrier

The microfluidic device with a detachable insert and base, utilizing a porous membrane to control cell and hydrogel injection, effectively simulates 3D tissue barriers, overcoming previous limitations in replicating in vivo tissue structures and functions, and enhancing drug distribution evaluation and cell analysis.

WO2024248445A1PCT designated stage expired Publication Date: 2024-12-05MEPSGEN CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007143
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-27
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing microfluidic devices face limitations in replicating the structure and function of 3D tissue barriers in vivo, particularly in simulating the spatial structure and biochemical complexity of living tissues, and struggle with bubble formation and reproducibility during cell and hydrogel injection, making them unsuitable for pharmaceutical applications.

Method used

A microfluidic device with a detachable insert and base, featuring a porous membrane and microchannels, allows for precise control of cell and hydrogel injection, suppressing bubble formation and enabling the simulation of 3D-3D tissue barriers through a structure that confines hydrogel using surface tension, facilitating mass transfer and automation.

Benefits of technology

The device effectively simulates the structure and function of 3D tissue barriers, enabling precise drug distribution evaluation and cell analysis, improving reproducibility and automating the organ simulation process, thus addressing the limitations of existing microfluidic devices.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000017
    Figure 000017
  • Figure 000018
    Figure 000018
  • Figure 000019
    Figure 000019
Patent Text Reader

Abstract

The present invention relates to a microfluidic device for simulating the structure and function of an in vivo tissue barrier. Particularly, the present invention relates to: a microfluidic device which replaces an animal model by simulating the structures and functions of a two-dimensional-three-dimensional connective tissue barrier, a three-dimensional tissue barrier, and a three-dimensional-three-dimensional tissue barrier, and thus can be used as a model for new drug development, toxicity evaluation, and the like; a method for culturing cells in the microfluidic device; and a method for simulating an organ or a body part, using the microfluidic device.
Need to check novelty before this filing date? Find Prior Art

Description

Microfluidic device for forming three-dimensional tissue barriers

[0001] The present invention relates to a microfluidic device that can be used as a model for new drug development and toxicity evaluation, etc. by replacing animal models by simulating the structure and function of a two-dimensional-three-dimensional connective tissue barrier, a three-dimensional tissue barrier, and a three-dimensional-three-dimensional tissue barrier in a living body, a method for culturing cells in a microfluidic device, and a method for simulating an organ or organ using a microfluidic device.

[0002] In addition, the present invention complements the shortcomings of existing microfluidic devices, so that the morphology and function of cultured cells and tissue barriers can be easily evaluated after cell culture.

[0003]

[0004] To address the ethical concerns and cross-species differences associated with using experimental animal models to test drug efficacy and side effects, organ-on-a-chip (organ-on-a-chip) systems have been developed. Organ-on-a-chip technology integrates organ tissues into a chip. Organ-on-a-chip technology mimics the morphological and physiological characteristics of specific organs by culturing cells on a small chip, thereby realizing desired functions. This technology allows for detailed studies of cell behavior and the mechanisms of physicochemical reactions in the microenvironment of specific organs, and can serve as models for new drug development and toxicity assessment.

[0005] In the development of organ chips, existing cell culture models using two-dimensional (2D) cell culture have the problem of not being able to explain the tissue-specific differentiated functions of many cell types or accurately predicting in vivo tissue functions and drug activity because cells are cultured two-dimensionally on the bottom of a petri dish.

[0006] In particular, in the case of brain tissue cells such as neurons and astrocytes that are in three-dimensional contact in vivo, the need for a three-dimensional cell culture model that accurately simulates the spatial structure and biochemical complexity of living tissue is increasing due to the limitations of the two-dimensional cell culture model.

[0007] 3D cell culture models closely mimic in vivo situations, allowing for the implementation of directional growth and the complexity of cell-to-cell connections in in vitro experiments. They are also useful for studying molecular-based tissue functions and capturing signaling pathways and drug responsiveness in various disease states compared to 2D cell culture models.

[0008] Meanwhile, microfluidics, developed alongside semiconductor processing technology, has enabled the mass production of structures with micro-scale dimensions with high precision. In particular, photolithography and soft lithography technologies have enabled the easy production of microchannel structures through stamping using semi-permanent molds. This has led to attempts to replicate microstructures, such as blood vessels and cell layers of organs, in vitro.

[0009] Previous studies have been conducted by fabricating chips consisting of polydimethylsiloxane (PDMS) microchannels and porous membranes using photolithography or soft lithography techniques, and then injecting cells through the inlet into specific microchannel regions within the microchannels connected between the inlet and outlet, thereby implementing the cell layer structure of an organ through cell culture within the chip. In addition, in a multi-channel structure, the height difference between the central and side channels, and the surface tension difference due to the curved surfaces of the micropillars in a structure where the central and side channels are divided into several micropillars, were utilized to confine the hydrogel only to the central channel, thereby forming a hydrogel structure for 3D cell culture.

[0010] However, organ chips using microfluidic devices made of PDMS material have limitations in applying them to the actual pharmaceutical industry, as drugs or proteins often adsorb to the PDMS surface and are lost. In addition, the method of injecting liquid into the microchannel through the inlet requires a high level of skill from the operator because care must be taken to prevent the generation of air bubbles due to friction with the microchannel surface. If air bubbles enter the microchannel inside the organ chip and expose the cells cultured inside the microchannel to air, the cell viability decreases rapidly, which presents a limitation in that it is impossible to form a tissue barrier.

[0011] In particular, the injection of high-viscosity hydrogels into microchannels through inlets requires greater expertise in controlling the injection rate. Multichannel microfluidic devices that confine hydrogels to the central channel using surface tension have limitations that make them difficult to apply in the actual pharmaceutical industry. Therefore, existing injection methods for multichannel organ-on-chips not only have low reproducibility in tissue barrier formation, but also present challenges in automating the entire organ simulation process using equipment based on mechanical and electronic control devices.

[0012] In addition, existing 3D organ chips using hydrogels were able to form 2D-3D tissue barriers because cells, proteins, and hydrogels could not be added after the hydrogel was confined in the central channel and hardened, but there are limitations in simulating the in vivo tissue structure and tissue-specific differentiation functions composed of many cells and proteins, such as 3D-3D tissue barriers.

[0013] Therefore, the inventors of the present invention have developed a microfluidic device to improve the problems of a multi-channel structured organ chip that injects cells, hydrogels, and solutions into microchannels through an inlet, and to more closely simulate the structure and function of a 3D-3D tissue barrier in vivo, thereby completing the present invention.

[0014]

[0015] (Prior art literature)

[0016] (Patent Document)

[0017] (Patent Document 1) Korean Patent No. 10-2313280

[0018] (Non-patent literature)

[0019] (Non-patent Document 1) Cho, H., et al. Three-dimensional blood-brain barrier model for in vitro studies of neurovascular pathology. Sci. Rep. 5, 15222 (2015).

[0020] (Non-patent Document 2) Booth, R. & Kim, H. Characterization of a microfluidic in vitro model of the blood-brain barrier (mu BBB). Lab Chip 12, 1784-1792 (2012).

[0021] (Non-patent Document 3) Ahn, SI, et al. Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms. Nature communications 11.1, 175 (2020).

[0022]

[0023] The present invention aims to provide a microfluidic device that exhibits a structure and function more similar to an in vivo tissue barrier compared to existing organ-on-a-chip by solving ethical issues and problems caused by differences between species arising from the use of experimental animal models and forming a structure of a three-dimensional tissue barrier or a three-dimensional-three-dimensional tissue barrier.

[0024] In addition, the present invention aims to provide a microfluidic device that exhibits a three-dimensional structure and function more similar to an in vivo tissue barrier than existing organ-on-a-chip by using a structure that suppresses the generation of bubbles inside a microchannel when injecting a solution, enables repeated injection of cells, proteins, and hydrogels, and enables material transfer through diffusion, and enables automation through a mechanical device and a control device.

[0025]

[0026] The present invention provides a microfluidic device comprising: an insert including a first central channel; a base including a first open chamber; and a porous membrane positioned between the insert and the base.

[0027] The present invention provides a method for culturing cells in a microfluidic device, comprising the steps of assembling the microfluidic device; inverting the microfluidic device, and then injecting second cells into a first open chamber and culturing them; injecting a hydrogel containing third cells into the first open chamber and then culturing them; and inverting the microfluidic device again, and then injecting first cells into a first central channel and culturing them.

[0028]

[0029] The microfluidic device of the present invention can be used to evaluate drug efficacy by simulating the main structures and material transport phenomena of various tissue barriers in a living body, including the blood-brain barrier.

[0030] Furthermore, the microfluidic device of the present invention enables precise quantification of drug distribution around tissue barriers. Since the insert is detachable from the base, cells contained within the microfluidic device can be selectively isolated without damage and used for analysis. Furthermore, the insert can be separated from the base, subjected to necessary processing, such as drug application, and then reassembled to observe cell responses.

[0031] In addition, the microfluidic device of the present invention uses an open chamber-shaped incubator to enable injection of cells, hydrogels containing cells, hydrogels containing three-dimensional cell structures, hydrogels containing biomaterials, and tissue samples collected from the human body, thereby realizing the three-dimensional spatial structure and biochemical complexity of cells in vivo, thereby better simulating the structure and function of tissue barriers.

[0032]

[0033] Figures 1 and 2 are cross-sectional views of a microfluidic device.

[0034] Figure 3 is a perspective view of a microfluidic device.

[0035] Figures 4 and 5 are exploded views and assembly diagrams of the microfluidic device.

[0036] Figure 6 is a cross-sectional view of a microfluidic device containing cells and hydrogel.

[0037] Figures 7 and 8 are cross-sectional views showing the configuration and method for attaching and detaching the insert and base.

[0038] Figures 9 and 10 are perspective views of the insert.

[0039] Figure 11 is a perspective view of the base.

[0040] Figure 12 is a plan view of the base.

[0041] Figure 13 is a bottom view of the base.

[0042] Figure 14 is a perspective view of the cover.

[0043] Figure 15 is a perspective view and a cross-sectional view showing the configuration and detachment method for attaching and detaching the insert and base.

[0044] Figure 16 is a plan view of a microfluidic device with an insert and a base attached.

[0045] Fig. 17 is a cross-sectional view A-A' and an enlarged cross-sectional view of a microfluidic device having an insert and base attached to Fig. 16.

[0046] Figure 18 is a front view of a microfluidic device with an insert and a base attached.

[0047] Figure 19 is a bottom view of a microfluidic device with an insert and a base attached.

[0048] Figure 20 is a perspective view of a microfluidic device including a cover.

[0049] Figure 21 is a perspective view showing the fluid flow within the microchannel included in the insert.

[0050] Figure 22 is a schematic diagram showing a cell culture method in a microfluidic device.

[0051] Figure 23 shows the morphology of human astrocytes cultured inside the first open chamber after co-culturing human cerebral vascular endothelial cells, human astrocytes, and human cerebral microvascular endothelial cells derived from induced pluripotent stem cells in a microfluidic device.

[0052]

[0053] Hereinafter, with reference to the attached drawings, embodiments and examples of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be implemented in various forms and is not limited to the embodiments and examples described herein.

[0054] Throughout this specification, whenever a part is said to "include" a component, this means that it may include other components, but not to the exclusion of other components, unless otherwise stated.

[0055] The present invention provides a microfluidic device comprising: an insert including a first central channel; a base including a first open chamber; and a porous membrane positioned between the insert and the base.

[0056] The term "microfluidic device" as used herein means a device that includes microchannels, etc., that allow fluid to flow on a substrate made of various materials including plastic, glass, metal, or silicon containing organic polymer materials.

[0057] The term "microchannel" as used herein means a microscopic channel having dimensions in the order of millimeters, micrometers, or nanometers through which a fluid can flow.

[0058] The term "insert" as used herein may mean, but is not limited to, an object of a shape that can be inserted into a groove formed in another object.

[0059] In one embodiment, the insert may be detachable from the base, and the base may include a groove into which the insert can be inserted. Preferably, the insert includes a first fastening head, and the base includes a second fastening head, such that the first fastening head and the second fastening head are engaged with each other so that the insert and the base can be attached and detached in a snap fit. At this time, in order to prevent leakage of the first central channel and the first open chamber, the porous membrane may receive strong pressure between the insert and the base to function as a gasket.

[0060] The term "fastening head" as used herein may be composed of an elastic material such as plastic, rubber, silicone, etc., and may be elastically deformed to achieve snap-fit ​​attachment / detachment, but is not limited thereto.

[0061] The term "snap fit" as used herein refers to a fastening method in which fastening force is formed by the interaction of grooves that engage each other, without any additional parts or fastening mechanisms.

[0062] In one embodiment, the first central channel may include an inlet and an outlet capable of inducing and controlling the perfusion of the liquid. Methods for inducing and controlling the perfusion may include, but are not limited to, a method utilizing a hydrostatic pressure difference between the inlet and the outlet, and a method of connecting an external pump to the inlet and the outlet.

[0063] In one embodiment, the first open chamber has a volume of 220 μL or less to maintain the liquid within the chamber when the microfluidic device is turned over after liquid injection, and a surface area in contact with air of 44 mm 2 It may be less than or equal to. In addition, the height (depth) of the first open chamber may be less than or equal to 5 mm, but is not limited thereto.

[0064] In one embodiment, the microfluidic device may be made of, but is not limited to, plastic, glass, metal, or silicon. Preferably, it may be made of plastic using injection molding technology.

[0065] In one embodiment, the first central channel may comprise tissue barrier cells.

[0066] The above tissue barrier cells may include vascular endothelial cells, skin cells, cancer cells, glandular cells, muscle cells, and epithelial cells of the bronchial tubes, colon, small intestine, pancreas, or kidney. Preferably, they may be vascular endothelial cells, and more preferably, they may be induced pluripotent stem cell-derived human brain microvascular endothelial cells (iPSC-derived HBMEC).

[0067] The term "cell" as used herein refers to biological cells, including plant cells, animal cells (e.g., mammalian cells), bacterial cells, and fungal cells.

[0068] The term "tissue barrier cell," as used herein, refers to a cell that maintains the specific structure of a tissue and protects it from external stimuli. Furthermore, it refers to a cell that selectively allows substances to pass through and maintains homeostasis in the concentration of substances within the tissue by utilizing strong bonds between tissue barrier cells or with the extracellular matrix. Tissue barrier cells include epithelial tissue cells and vascular endothelial cells.

[0069] In one embodiment, the first open chamber may comprise internal tissue cells and a hydrogel.

[0070] The above internal tissue cells may include astrocytes, pericytes, neurons, neural stem cells, glial cells, cardiomyocytes, smooth muscle cells, intestinal epithelial cells, keratinocytes, dermal fibroblasts, podocytes, and glomerular endothelial cells. Preferably, they may be astrocytes or pericytes, and more preferably, human astrocytes (HA) or human brain vascular pericytes (HBVP).

[0071] The term "internal tissue cell" as used herein means a cell that constitutes an organ or tissue of the human body, and includes all cells that constitute human tissue, including but not limited to epithelial tissue, muscle tissue, nervous tissue, or connective tissue.

[0072] The hydrogel may be at least one selected from the group consisting of collagen, laminin, hyaluronic acid, minerals, fibrin, fibronectin, elastin, peptides, polyethylene glycol, and alginate. Preferably, the hydrogel may be a collagen gel, fibrin gel, laminin gel, matrigel, animal-derived tumor basement membrane extract gel, tissue decellularized extracellular matrix gel, peptide gel, polyethylene glycol gel, or alginate gel, but is not limited thereto. More preferably, it is a laminin gel or matrigel.

[0073] The hydrogel may be injected from the outside of the microfluidic device into the upper portion of the first open chamber after the microfluidic device is turned over, and spatially confined within the first open chamber.

[0074] The term "hydrogel" as used herein refers to a material having a three-dimensional polymer network structure that is cross-linked by cohesive forces such as covalent bonds, hydrogen bonds, van der Waals bonds, or physical bonds and can swell by containing a large amount of water inside in an aqueous solution.

[0075] In one embodiment, the insert can be separated from the base to separate one or more cells selected from the group consisting of cells contained in the first central channel, cells contained in the first open chamber, and cells attached to the porous membrane, and cell analysis such as genetic analysis can be performed using the separated cells.

[0076] In one embodiment, the insert is separated from the base, and after performing necessary processing, such as drug application to the first central channel, the insert is reassembled to the base to observe cell responses.

[0077] The present invention provides a method for culturing cells in a microfluidic device, comprising the steps of assembling a microfluidic device comprising an insert including a first central channel; a base including a first open chamber; and a porous membrane positioned between the insert and the base, wherein the insert is detachable from the base; inverting the microfluidic device, injecting second cells into the first open chamber and culturing them; injecting a hydrogel including third cells into the first open chamber and culturing them; inverting the microfluidic device again, injecting first cells into the first central channel and culturing them.

[0078] In one embodiment, the first central channel includes an inlet and an outlet capable of inducing and controlling perfusion of a liquid, the first open chamber has an upper portion that is not closed and is connected to the outside, the hydrogel including the second cells and the third cells may be injected through the upper portion of the first open chamber, and the first cells may be injected through the inlet of the first central channel.

[0079] In one embodiment, the first cell is selected from the group consisting of vascular endothelial cells, skin cells, cancer cells, glandular cells, muscle cells, and epithelial cells of the bronchial tubes, colon, small intestine, pancreas, or kidney; the second cell is selected from the group consisting of pericytes, glial cells, cardiomyocytes, smooth muscle cells, intestinal epithelial cells, keratinocytes, dermal fibroblasts, podocytes, and glomerular endothelial cells; and the third cell may be selected from the group consisting of astrocytes, neural cells, and neural stem cells. Preferably, the first cell may be a vascular endothelial cell, the second cell may be a pericyte, and the third cell may be an astrocyte. More preferably, the first cell may be a human brain microvascular endothelial cell (HBMEC), the second cell may be a human brain vascular pericyte (HBVP), and the third cell may be a human astrocyte (HA). Most preferably, the first cell may be an induced pluripotent stem cell-derived human brain microvascular endothelial cell (iPSC-derived HBMEC), the second cell may be a human brain vascular pericyte (HBVP), and the third cell may be a human astrocyte (HA).

[0080] In one embodiment, the present invention comprises a step of assembling a microfluidic device comprising an insert including a first central channel; a base including a first open chamber; and a porous membrane positioned between the insert and the base, wherein the insert is detachable from the base; and after turning the microfluidic device over, 106 A step of injecting 1 to 50 μl of human brain vascular pericytes (HBVP) at a concentration of cells / ml into the first open chamber and culturing them; 10 3 A step of injecting a hydrogel containing 1 to 50 μl of human astrocytes (HA) at a concentration of 10 cells / ml or more into the first open chamber and culturing the hydrogel; after inverting the microfluidic device again, 10 5 A method for culturing cells in a microfluidic device is provided, comprising a step of injecting 1 to 50 μl of induced pluripotent stem cell-derived human brain microvascular endothelial cells (iPSC-derived HBMEC) at a concentration of 10 cells / ml or more into the first central channel and culturing the cells.

[0081] The present invention provides a method for simulating an organ or organs in a microfluidic device, comprising: an insert including a first central channel; a base including a first open chamber; and a porous membrane positioned between the insert and the base, wherein the insert is detachable from the base.

[0082] The organ or organs may include, but are not limited to, the blood-brain barrier, lungs, liver, heart, retina, colon, small intestine, pancreas, and kidneys. Preferably, the organ or organ may be the blood-brain barrier (BBB).

[0083] Hereinafter, the microfluidic device of the present invention will be described in detail with reference to the drawings. The present invention may include a microfluidic device embodied in the form of FIGS. 1 to 21, but is not limited thereto. In particular, although specific embodiments of the microfluidic device of the present invention are illustrated in FIGS. 22 to 23, the present invention is not limited to specific embodiments, and includes various modifications that can be implemented by a person of ordinary skill in the art to which the present invention pertains.

[0084] The microfluidic device of the present invention includes an insert (100), a base (200), and a porous membrane (300) positioned between the insert (100) and the base (200).

[0085] Referring to FIGS. 1 to 3, the insert (100) includes a first central channel (110), and the base (200) includes a first open chamber (210).

[0086] Referring to FIGS. 4 and 5, the porous membrane (300) of the microfluidic device may be present between the first central channel (110) and the first open chamber (210).

[0087] Referring to FIG. 6, the first central channel (110) of the microfluidic device may include a first cell (111), and the first open chamber (210) may include a second cell (211), a third cell (212), and / or a hydrogel (213). In one embodiment, the first cell (111) may be cultured by being attached to the upper surface of the porous membrane (300), the second cell (211) may be cultured by being attached to the lower surface of the porous membrane (300), and the third cell (212) may be cultured in 3D within the hydrogel (213).

[0088] Referring to FIGS. 7 and 8 and 15, the base (200) of the microfluidic device may include an insert insertion groove (201) into which an insert (100) may be inserted, and the insert (100) may be detachable from the base (200). In addition, the insert (100) may include a first fastening head (101), and the base (200) may include a second fastening head (202), and the first fastening head (101) and the second fastening head (202) may be hooked to each other so that the insert (100) and the base (200) may be detachable in a snap fit.

[0089] Referring to FIGS. 9 and 10, the insert (100) of the microfluidic device may include a first central channel inlet (112) and an outlet (113). The first central channel inlet (112) and outlet (113) may be connected to the first central channel (110) in a tubular form.

[0090] Referring to FIGS. 11 to 13 and 15 to 19, the base (200) of the microfluidic device may have a structure in which one or more inserts (100) can be detachably attached. Preferably, eight inserts (100) may be detachably attached.

[0091] Referring to FIGS. 14 and 20, the microfluidic device may include a cover (400).

[0092] Referring to FIG. 21, a fluid can be injected through the first central channel inlet (112) included in the insert (100) of the microfluidic device, and the fluid can be perfused through the first central channel (110) toward the first central channel outlet (113).

[0093] The present invention will be described in more detail through the following examples; however, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[0094]

[0095] (Example 1)

[0096] Optimization of the first open chamber structure design

[0097]

[0098] In order to confirm the condition under which the liquid inside the first open chamber does not flow out of the microfluidic device when the microfluidic device of the present invention is turned over, an experiment was conducted to confirm the width, length, depth, volume, and surface area in contact with air of the first open chamber as follows.

[0099] An open chamber was fabricated by attaching a frame structure made of polydimethylsiloxane to a glass slide, and a volume of water sufficient to fill the chamber was measured and injected into the chamber. When the chamber was turned over, it was confirmed whether the water remained inside the chamber.

[0100] When the chamber was turned over under conditions of various open chamber widths, lengths, depths, volumes, and surface areas, whether liquid was maintained inside the chamber was checked, and the results are shown in Table 1 below.

[0101] Open chamber design conditionsIf the chamber is turned overWhether liquid is maintained inside the chamberWidth (mm)Length (mm)Depth (mm)Surface area (mm) 2 )Volume (μL)49436144Liquid retention49536180Liquid retention49636216Liquid not retention410440160Liquid retention410540200Liquid retention410640240Liquid not retention411444175Liquid retention411544220Liquid retention411644264Liquid not retention412448192Liquid not retention412548240Liquid not retention412648288Liquid not retention66536180Liquid retention

[0102] As shown in Table 1 above, the volume is 220 μL or less, and the surface area is 44 mm 2 In the following cases, it was confirmed that the liquid was maintained inside the chamber.

[0103] When the chamber was filled with water and the chamber was turned over, the liquid was maintained inside the chamber when the surface tension acting on the liquid inside the chamber was greater than the gravity acting on the liquid inside the chamber. Therefore, it was confirmed that as the surface tension acting on the liquid inside the chamber increased, the volume of the liquid maintained inside the chamber increased when the chamber was turned over.

[0104] The present invention is to form a tissue barrier by culturing cells on both the upper and lower sides of a porous membrane inside a microfluidic device, and it is very important that the liquid in the lower open chamber is maintained inside the chamber during the step of attaching cells to the upper side of the porous membrane.

[0105] Therefore, the volume of the first open chamber of the microfluidic device of the present invention is 220 μL or less, and the surface area is 44 mm 2 It was confirmed that it is desirable to maintain the following.

[0106]

[0107] (Example 2)

[0108] Fabrication of a blood-brain barrier (BBB)-mimetic microfluidic device

[0109]

[0110] Using the assembled microfluidic devices shown in Figs. 1 to 21, a microfluidic device capable of simulating the blood-brain barrier (BBB) ​​was manufactured in the following manner.

[0111] The process of forming a blood-brain barrier simulation model using a microfluidic device is as shown in Figure 22. Specifically, (1) the microfluidic device is turned over and then 10 615 μl of human cerebrovascular pericyte (HBVP) cells at a concentration of cells / ml were injected into the first open chamber, (2) incubated for 30 minutes to allow the pericyte cells to attach evenly to the surface of the porous membrane, and then the culture medium was replaced. (3) 5×10 cells embedded in Matrigel were placed in the first open chamber with the culture medium present. 6 After injecting 4 μl of human stellate cells (HA) at a concentration of cells / ml into the first open chamber, the Matrigel was incubated for 30 minutes to harden. (4) After inverting the microfluidic device again, 7×10 7 After injecting 7 μl of human brain microvascular endothelial cells (iPSC-derived HBMEC) at a concentration of 10 cells / ml into the first central channel, (5) the culture medium was replaced after culturing for 1 hour.

[0112] To confirm the formation of a blood-brain barrier-mimetic model through co-culture of human cerebral vascular endothelial cells, human astrocytes, and human cerebral microvascular endothelial cells derived from induced pluripotent stem cells in a microfluidic device, the co-culture of human astrocytes and human cerebral microvascular endothelial cells inside the microfluidic device was visualized by fluorescence and then examined using a confocal microscope (LSM 700, Carl Zeiss, Oberkochen, Germany).

[0113] As a result, as shown in Fig. 23, it was confirmed that while the microfluidic device was turned over and human brain microvascular endothelial cells derived from induced pluripotent stem cells were cultured in the first central channel, the astrocytes embedded in the Matrigel and the culture medium injected into the first open chamber were positioned in the opposite direction of gravity, but were maintained and cultured inside the chamber.

[0114]

[0115] (Explanation of symbols)

[0116] 100: Insert

[0117] 101: First fastening head

[0118] 110: First central channel

[0119] 111: First cell

[0120] 112: Entrance to the first central channel

[0121] 113: Exit 1 of the central channel

[0122] 200: Base

[0123] 201: Insert insertion groove

[0124] 202: Second fastening head

[0125] 210: First open chamber

[0126] 211: Second cell

[0127] 212: Third cell

[0128] 213: Hydrogel

[0129] 300: Porous membrane

[0130] 400: Cover

Claims

1. An insert including a first central channel; a base comprising a first open chamber; and A microfluidic device characterized by comprising a porous membrane positioned between the insert and the base.

2. A microfluidic device according to claim 1, characterized in that the insert is detachable from the base.

3. A microfluidic device according to claim 2, characterized in that the base includes a groove into which the insert can be inserted.

4. In the second paragraph, the insert includes a first fastening head, The above base includes a second fastening head, A microfluidic device characterized in that the first fastening head and the second fastening head are hooked to each other so that the insert and the base are attached and detached in a snap fit.

5. A microfluidic device according to claim 1, characterized in that the first central channel includes an inlet and an outlet capable of inducing and controlling the perfusion of a liquid.

6. A microfluidic device according to claim 1, characterized in that the first central channel includes tissue barrier cells.

7. A microfluidic device according to claim 6, characterized in that the tissue barrier cells are selected from the group consisting of vascular endothelial cells, skin cells, cancer cells, secretory gland cells, muscle cells, and epithelial cells of the bronchial tubes, colon, small intestine, pancreas, and kidney.

8. A microfluidic device according to claim 1, characterized in that the first open chamber is connected to the outside because the upper portion is not closed.

9. A microfluidic device according to claim 1, characterized in that the first open chamber includes internal tissue cells and a hydrogel.

10. A microfluidic device according to claim 9, characterized in that the internal tissue cells are selected from the group consisting of stellate cells, pericytes, neurons, neural stem cells, glial cells, cardiomyocytes, smooth muscle cells, intestinal epithelial cells, keratinocytes, dermal fibroblasts, podocytes, and glomerular endothelial cells.

11. A microfluidic device according to claim 9, characterized in that the hydrogel is selected from the group consisting of collagen, laminin, hyaluronic acid, mineral, fibrin, fibronectin, elastin, peptide, polyethylene glycol, and alginate.

12. A microfluidic device according to claim 1, characterized in that the first open chamber has a volume of 220 μL or less.

13. In the first paragraph, the first open chamber is 44 mm 2 A microfluidic device characterized by having a surface area below.

14. A microfluidic device characterized in that, in the first paragraph, the insert can be separated from the base to separate one or more cells selected from the group consisting of cells included in the first central channel, cells included in the first open chamber, and cells attached to the porous membrane.

15. A microfluidic device according to claim 1, characterized in that the microfluidic device is made of plastic, glass, metal or silicon.

16. A step of assembling a microfluidic device, comprising: an insert including a first central channel; a base including a first open chamber; and a porous membrane positioned between the insert and the base, wherein the insert is detachable from the base; A step of inverting the microfluidic device, then injecting the second cell into the first open chamber and culturing it; A step of injecting a hydrogel containing third cells into the first open chamber and then culturing them; and After turning the above microfluidic device over again, a step of injecting the first cell into the first central channel and culturing it. A method for culturing cells in a microfluidic device, comprising:

17. In paragraph 16, The first central channel includes an inlet and an outlet capable of inducing and controlling the perfusion of the liquid; The first open chamber is connected to the outside because the upper part is not closed, The hydrogel containing the second cell and the third cell is injected through the upper portion of the first open chamber, A cell culture method in a microfluidic device, characterized in that the first cell is injected through the first central channel inlet.

18. In paragraph 16, The first cell is selected from the group consisting of vascular endothelial cells, skin cells, cancer cells, secretory gland cells, muscle cells, and epithelial cells of the bronchial tubes, colon, small intestine, pancreas, or kidney; The second cell is selected from the group consisting of stromal cells, glial cells, cardiomyocytes, smooth muscle cells, intestinal epithelial cells, keratinocytes, dermal fibroblasts, podocytes, and glomerular endothelial cells; A method for culturing cells in a microfluidic device, characterized in that the third cell is selected from the group consisting of astrocytes, neurons, and neural stem cells.

19. A cell culture method in a microfluidic device, characterized in that in claim 16, the first open chamber has a volume of 220 μL or less.

20. In the 16th paragraph, the first open chamber is 44 mm 2 A method for culturing cells in a microfluidic device, characterized by having the following surface area.

21. An insert including a first central channel; a base including a first open chamber; and a porous membrane positioned between the insert and the base, A method for simulating an organ or organs in a microfluidic device, wherein the insert is detachable from the base.

22. In the 21st paragraph, the first open chamber has a volume of 220 μL or less and a length of 44 mm 2 A method for simulating an organ or organs in a microfluidic device, characterized in that it has the following surface area.

Citation Information

Patent Citations

  • Three-dimensional biological tissue culture method, device, and system

    JP2020010683A

  • Dry fog system

    KR102273396B1

  • Microengineered tissue barrier system

    KR102313280B1

  • LED lamp for streetlight

    KR102507868B1

  • Integrated microfluidic system for culturing and testing

    WO2018030958A1